Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody c...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosterwijk-Wakka, Jeannette C., de Weijert, Mirjam C.A., Franssen, Gerben M., Leenders, William P.J., van der Laak, Jeroen A.W.M., Boerman, Otto C., Mulders, Peter F.A., Oosterwijk, Egbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351300/
https://www.ncbi.nlm.nih.gov/pubmed/25748241
http://dx.doi.org/10.1016/j.neo.2014.12.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351300/
https://www.ncbi.nlm.nih.gov/pubmed/25748241
http://dx.doi.org/10.1016/j.neo.2014.12.011

Ejemplares similares